4/A: Protara Therapeutics Executive Corrects Beneficial Ownership Report
SEC Filing (Form 4 Amendment)
Jacqueline Zummo, Chief Scientific Operations Officer of Protara Therapeutics, files an amendment to a previous Form 4 to correct the reported amount of securities beneficially owned.
Summary
- Jacqueline Zummo, Chief Scientific Operations Officer of Protara Therapeutics, filed an amended Form 4 with the SEC.
- The amendment corrects a misreporting in the original Form 4 filed on January 28, 2025, regarding the amount of securities beneficially owned following a transaction.
- The corrected filing indicates that Zummo beneficially owns 120,085 shares of Protara Therapeutics common stock.
Sentiment
Score: 7
Explanation: The document is a routine correction of a regulatory filing, indicating a neutral sentiment. The correction itself doesn't suggest any underlying issues with the company's performance or prospects.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. Amendments are sometimes necessary to correct errors or omissions in the original filings.
Key Dates
| Date | Description |
|---|---|
| 01/24/2025 | Date of earliest transaction |
| 01/28/2025 | Date of original Form 4 filing that was amended |
| 03/28/2025 | Date of amended Form 4 filing |
Keywords
Form 4, amendment, beneficial ownership, Protara Therapeutics, TARA, Jacqueline Zummo, securities, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.